Clinical Trial Update: Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer [EARLY_Phase 1]

View source ↗

Summary

This early-phase 1 trial evaluated whether AZD6244 (selumetinib) can increase estrogen receptor expression and enhance anti-estrogen response in estrogen recept…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AZD6244 (selumetinib) (selumetinib)

Snippet

Sponsor: University of Miami | Conditions: Breast Cancer | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2014-07-02